Advertisement
Advertisement

AGEN

AGEN logo

Agenus Inc.

3.23
USD
Sponsored
-0.17
-4.86%
Jun 05, 16:00 UTC -4
Closed
exchange

After-Market

3.27

+0.04
+1.33%

Agenus Inc. Profile

About

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.

Info & Links

CEO

Garo H. Armen

Headquarters

3 FORBES ROAD
LEXINGTON, MA 02421, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.agenusbio.com

Auditor

KPMG LLP

Share holders

178

Employees

81

Agenus Inc. Statistics

Valuation Measures

Market Capitalization2

136.30M

Enterprise Value

131.49M

Enterprise Value/EBITDA(ttm)

8.44

Price to Earnings Ratio(ttm)

9.47

Price to Sales(ttm)

1.50

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

99.09%

Operating Margin(ttm)

20.41%

Profit Margin(ttm)

-8.53%

Return on Equity(ttm)

-7.65%

Return on Invested Capital(ttm)

-2.33%

Return on Assets(ttm)

11.01%

Income Statement

Revenue(ttm)

123.87M

Revenue Per Share(ttm)

2.97

Gross Profit(ttm)

122.98M

EBITDA(ttm)3

15.57M

Net Income Available to Common(ttm)

64.39M

Diluted EPS(ttm)

-0.46

Share Statistics

Beta (5Y Monthly)

1.60

52-Week Change

-42.63%

S&P 500 52-Week Change

23.05%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

41.64M

Dividend Yield

0.00%

Float4

36.29M

% Held by Insiders

5.50%

% Held by Institutions

61.46%

Balance Sheet

Total Cash(mrq)

35.00M

Total Cash Per Share(mrq)

0.84

Total Debt(mrq)

30.19M

Total Debt/Equity(mrq)

-16.07%

Current Ratio(mrq)

0.41%

Quick Ratio(mrq)

0.41%

Book Value Per Share(mrq)

-7.87

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.60

Free Cash Flow(ytd)

-76.84M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement